UFP Technologies (UFPT) Q2 2026 earnings summary

Executive summary

• Q2 2026 net sales reached a record $174.0 million, up 15.1% year-over-year, with broad-based MedTech growth and net income of $20.9 million, up 21.4% from Q2 2025.

• Year-to-date net sales were $328.2 million, a 9.6% increase, with net income of $38.3 million, up 11.6% year-over-year.

• Growth was diversified across customers and products, with top five customers up 14.7% and the rest of MedTech up 19.7%.

• Investments in Dominican Republic operations are enhancing capacity and efficiency, with early operational benefits and near-term margin pressure in U.S. operations.

• CEO transition and leadership strengthening impacted SG&A expenses.

Financial highlights

• Q2 2026 organic sales growth was 12.4%, with gross margin rising to 29.3% from 28.8% year-over-year.

• Adjusted EPS for Q2 2026 was $2.92, up 16.8% year-over-year; six-month diluted EPS was $4.92.

• Operating income for Q2 2026 grew 15.5% to $28.1 million; adjusted EBITDA rose 14.3% to $36.4 million.

• SG&A expenses increased due to higher headcount, compensation, and CEO transition costs.

• Cash from operations was $15.6 million in Q2 and $18.8 million for the first half; capital expenditures were $1.2 million in Q2.

Outlook and guidance

• Organic growth is expected to return to the long-term target range of 6%-9% for the remainder of 2026.

• Management plans to add manufacturing capacity and pursue disciplined acquisitions.

• No formal guidance provided for the rest of 2026; existing resources and credit facility are expected to fund requirements.